Drugs / Autologous Tumor Infiltrating Lymphocytes LN-145-S1
Autologous Tumor Infiltrating Lymphocytes LN-145-S1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03449108 | Apr 2018 → Apr 2027 expected | bone giant cell tumor, dedifferentiated chondrosarcoma, malignancy in giant cell tumor of bone, osteosarcoma +7 | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Tumor Infiltrating Lymphocytes LN-145-S1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03449108 ↗ |
| Action | Deplete | “The T cells may specifically recognize, target, and kill the tumor cells.” NCT03449108 ↗ |
| Modality | Cell therapy | “LN-145-S1 is made using a modified process that chooses a specific portion of the T-cells.” NCT03449108 ↗ |
| Route | Intravenous | “LN-145-S1 IV over 45 minutes” NCT03449108 ↗ |